Navigation Links
Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update
Date:11/12/2013

ng NSI-566 preclinical program in multiple indications where loss of cognitive function is prevalent."

"We thank our shareholders for their continued support; we begin the fourth quarter on solid financial footing, with cash on-hand to cover our corporate and clinical budgets for the next two years," said Richard Garr, Neuralstem's President and CEO. "Dr. Johe and I extend our deep appreciation to our patients, and their families and caregivers, for their continued support and dedication to our work in ALS and other debilitating diseases and conditions of the central nervous system. We thank our team of world-class clinical collaborators and investigators around the globe, innovators all, who we are proud to call our partners."

Third Quarter Clinical Program and Business Highlights In August, the company completed dosing of the NSI-189/major depressive disorder (MDD) Phase Ib trial. The trial of Neuralstem's lead neurogenic small molecule drug was designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics effect of escalating doses of NSI-189 for 28 daily administrations in 24 depressed patients in three cohorts. Data is being compiled.

In August, University of California, Irvine researchers published a paper in the scientific journal, CELL TRANSPLANTATION – THE REGENERATIVE MEDICINE JOURNAL, which reported that NSI-566 reversed cognitive defect and improved cognitive function in rats that had received radiation to the brain. "Transplantation of Human Fetal-Derived Neural Stem Cells Improves Cognitive Function Following Cranial Irradiation" used an animal model of radiation treatment for  brain cancer and showed that brain-irradiated rats that received NSI-566 transplants had improved cognitive function, including improved hippocampal spatial memory, as assessed by two separate cognitive tasks.

In September, Neuralstem's NSI-566/ALS Phase II dose escalation and safety trial commenced, with the first
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
10. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
11. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... lend materials new characteristics are generally complicated and therefore ... to astonishment when scientists report on new methods which ... they use economically priced starting materials but also do ... framework made of polystyrene This is exactly ...
... BioSpace added Kansas to its annual promotional campaign of biotechnological, ... , , ... , , (Logo:   ... The leading employment Web site for the ...
... , July 29 Omeros Corporation (Nasdaq: ... equity financing facility under which it may sell up to ... to Azimuth Opportunity, Ltd. (the "investor") over a 24-month period. ... free to enter into and consummate other equity, debt and ...
Cached Biology Technology:Empa grows 'sea urchin'-shaped structures 2BioSpace Showcases the Midwest's Growing Life Science Region 2BioSpace Showcases the Midwest's Growing Life Science Region 3Omeros Secures $40 Million Committed Equity Financing Facility 2Omeros Secures $40 Million Committed Equity Financing Facility 3Omeros Secures $40 Million Committed Equity Financing Facility 4
(Date:7/10/2014)... the Straits of Mackinac reverse direction every few days, ... would quickly contaminate shorelines miles away in both lakes ... Michigan study commissioned by the National Wildlife Federation. , ... animations, oil from a hypothetical pipeline break reached Mackinac ... Blanc Island after two days. All three islands are ...
(Date:7/10/2014)... The yellow crazy ant Anoplolepis gracilipes is ranked ... responsible for catastrophic ecological impacts on islands. A new study ... examines and assesses the effects and dangers of the ... of the mature palm forest of the Valle de Mai, ... palm forest of Valle de Mai is a unique ecosystem ...
(Date:7/10/2014)... Columbia University Medical Center (CUMC) researchers have created a ... retinitis pigmentosa (RP), a leading cause of vision loss. ... of induced pluripotent stem (iPS) cell technology to transform ... as a patient-specific model for disease study and preclinical ... H. Tsang, MD, PhD, showed that a form of ...
Breaking Biology News(10 mins):Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 2Straits of Mackinac 'worst possible place' for a Great Lakes oil spill 3Invasion of yellow crazy ant in a Seychelles UNESCO palm forest: Threats and solutions 2Patient-specific stem cells and personalized gene therapy 2Patient-specific stem cells and personalized gene therapy 3
... of proteins and other chemicals that underlies most ... molecules that accelerate chemical reactions between molecules. The ... the synthesis of chemicals and pharmaceuticals, devise new ... therapies. In the August 16 issue of ...
... has journeyed to this section of Antarcticas Amundsen Sea, but ... researchers and a Boerne High School science teacher will join ... sail on a two month expedition. The trip, ... to UTSA, is designed to study the relationship of sea ...
... evidence reported in the August issue of Cell Stem Cell, ... how the HIV/AIDS virus leads to learning and memory deficits, ... the surface of the virus not only kills some mature ... prevents the birth of new brain cells by crippling adult ...
Cached Biology News:MGH researchers describe new way to identify, evolve novel enzymes 2Texas researchers and educators head for Antarctica 2HIV is a 'double hit' to the brain 2
... 26] to Presenilin 2 Alzheimer's disease ... the disease carry mutations in the presenilin ... protein (APP). These disease-linked mutations result in ... amyloid-beta (main component of amyloid deposits found ...
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
Biology Products: